Summary Daunorubicin (DNR) is a major front-line drug in the treatment of childhood acute lymphoblastic leukaemia (ALL). Previously, we showed that in vitro resistance to DNR at diagnosis is related to a poor long-term clinical outcome in childhood ALL and that relapsed ALL samples are more resistant to DNR than untreated ALL samples. In cell line studies. idarubicin (IDR). aclarubicin (ACR) and mitoxantrone (MIT) showed a (partial) lack of cross-resistance to the conventional anthracyclines DNR and doxorubicin (DOX). but clinical studies in childhood ALL have been inconclusive about the suggested lack of cross-resistance. In the present study we determined the in vitro cross-resistance pattern between DNR. DOX. IDR. ACR 
Two-thirds of children with newly diagnosed acute lymphoblastic leukaemia (ALL) can now be cured with combination chemotherapy, but chemotherapy fails in the remaining third, mainly because the leukaemia relapses (Niemeyer et al.. 1991) . Despite intensive salvage chemotherapy. children with relapsed ALL still have a poor prognosis, and only one-third of them can be cured (Henze et al., 1991) . Anthracychnes, such as daunorubicin (DNR) and doxorubicin (DOX) . are commonly used in combination with several other classes of drugs in the treatment of childhood ALL. However, their clinical use is limited by cardiotoxicity and the development of drug resistance (Weiss, 1992) . Previously, we showed that samples from children with relapsed ALL are more resistant to DNR than samples from children with untreated ALL (Pieters et al.. 1992 : Klumper et al.. 1993 .
Anthracycline analogues lacking cross-resistance may circumvent resistance to DNR or DOX and may improve chemotherapy for relapsed childhood ALL. Many analogues have been developed since DNR and DOX were discovered in the early 1960s, but only a few have reached clinical trials (Muggia and Green, 1991) . Idarubicin (IDR) , aclarubicin (ACR) and the structurally closely related mitoxantrone (MIT) show a (partial) lack of cross-resistance to DNR and DOX in different cell lines (Hill et al.. 1985; Coley et al.. 1989; Erttmann et al.. 1991) . Clinical studies with anthracycline analogues in childhood ALL are inconclusive about the suggested lack of cross-resistance. since no randomised comparative studies have been reported to date. In the present study, we determined the in vitro cross-resistance pattern between DNR. DOX. IDR, ACR and MIT within an uniform group of fresh samples obtained from 48 children with untreated ALL and 39 children with relapsed ALL.
Materials and methods

Drugs
We tested the following drugs: DNR (Polyfarma, The Netherlands), DOX lands), MIT (Lederle. The Netherlands). ACR was a generous gift from Lundbeck (Copenhagen. Denmark). DNR, DOX and IDR were dissolved in distilled water. ACR was dissolved in ethanol. MIT was obtained in soluble form. All drugs were further diluted with RPMI-1640 (Dutch modification. Gibco, Uxbridge. UK) and stored at -20'C in stock solutions of 50gml-1' (MIT). l00 gml-' (DNR, IDR) and 400 g ml-l (DOX. ACR). Microculture plates were prepared with serial 4-fold drug dilutions derived from these stock solutions, and the plates were stored at -20°C to facilitate large-scale testing. We used in vitro concentration ranges that covered clinical plasma concentrations (Table I) . Anthracycines can be safely stored at -20'C up to 9 months without decomposition (Scott et al.. 1986) . and without loss of in vitro anti-leukaemic efficacy of all drugs tested (data not shown).
Leukaemic samples Bone marrow (BM) and or peripheral blood (PB) samples were obtained, with informed consent, from 48 children with newly diagnosed ALL and 39 children with relapsed ALL. All children from the relapsed ALL group had previously been exposed to DNR and or DOX as part of multidrug front-line chemotherapy. None of the children with relapsed ALL had been tested before at initial diagnosis. Samples were processed within 24 h after collection.
Mononuclear cells were isolated by Ficoll density-gradient centrifugation (Ficoll Paque, density 1.077g ml-'; Pharmacia, Sweden) and washed twice in RPMI-1640 containing 0.1% bovine serum albumin. Representative in vitro drug resistance data can be generated if more than 70% ALL cells are present after a 4 day cell culture. since in vitro drug resistance will be overestimated if more than 30% contaminating nonmalignant cells are present (Kaspers et al.. 1994) . To increase the number of evaluable cell cultures, the leukaemic cell population was enriched in 10 87 samples by removing contamiinating non-malignant cells using monoclonal antibodies linked to magnetic beads (Dynabeads M450. Dynal. Norway). We incubated cell suspensions (50 x 106 cells ml-') for 30 mmn at 37'C with one or a combination of the following mouse monoclonal antibodies (ITK, The Netherlands) directed against myeloid cells (CD13 and CD1 5, dilution 1:50 May-Gru5nwald Giemsa-counterstained cytospins of control cells were made and showed that all samples contained ) 80% leukaemic cells at onset of the cell culture and ) 70% leukaemic cells after a 4 day cell culture. After 4 days. we added 10 jii of 5 mg ml-' MIT to each well and the microculture plates were incubated for another 6 h. The tetrazolium salt MTT is reduced to dark-coloured formazan crystals by viable cells only. Formazan crystals were dissolved with 100 pi of acidified isopropanol. The optical density (OD) (Figure 1) . We calculated the resistance ratios, i.e. the ratio of the median LC50 values from the relapsed and untreated ALL group; the resistance ratios ranged from 1.5 to 2.7 (Table III) . (Table IV) . Figure 2 shows the cross-resistance pattern in childhood ALL between the front-line drug DNR vs DOX, IDR, ACR and MIT. Separate analyses of the untreated (n = 48) and relapsed (n = 39) ALL groups gave comparable Spearman rank correlation coefficients. A strong correlation was found between DNR, DOX, IDR and MIT (rho = 0.75-0.84), and to a lesser extent between ACR and the other four drugs (rho = 0.50-0.57). values of both groups showed considerable overlap. This suggests that DNR resistance in relapsed ALL may already be present at first diagnosis and that some children with relapsed ALL remained chemosensitive to DNR. Cell lines often express a 10-to more than 100-fold drug-induced resistance, whereas we found relative low resistance ratios for the anthracyclines in childhood relapsed ALL, ranging from 1.5 to 2.7. However, these resistance ratios were based upon the ratio of the median LC_% of the relapsed compared with the untreated ALL group; inter-patient chemosensitivities differed over 100-fold. Although Hill et al. (1989) have argued that cell lines expressing low levels of drug-induced resistance would be more suitable for the study of clinically relevant resistance mechanisms, our results based on patient samples suggest that cell lines with both low and high levels of drug-induced resistance could be used to investigate drug resistance. These large inter-patient variations probably reflect the clinical heterogeneity of tumour samples, which hampers the extrapolation of results from single cell line studies to clinically relevant results. No anthracycine resistance mechanisms or strategies to modulate anthracycine resistance with major clinical relevance in childhood ALL have been identified so far. P-glycoprotein expression has been most extensively studied in childhood ALL. but most studies could not detect significant differences in P-glycoprotein expression between untreated and relapsed childhood ALL samples (Ubezio et al., 1989 : Tawa et al.. 1990 : Mizuno et al., 1991 Gekeler et al.. 1992 : Pieters et al.. 1992 : Brophy et al., 1994 , whereas the latter samples were significantly more resistant to anthracycines in the present study. Moreover, we showed previously that neither verapamil nor cyclosporin A could modulate in vitro DNR resistance in childhood ALL (Pieters et al., 1992) . Although multiple factors are likely to cause drug resistance, short-term cell culture drug resistance assays, such as the MTT assay, measure the end point of all possible resistance mechanisms, i.e. leukaemic cell kill, which is shown to be of predictive value in childhood ALL (Pieters et al., 1991) .
Our results suggest that IDR, ACR and MIT do not have a higher therapeutic index than DNR since their in vitro anti-leukaemic activity was paralleled by their toxicity on normal cells, represented by the MTD. We found that IDR was the most active anti-leukaemic drug in vitro, a fact that is well known (Fields and Koeller, 1991) . One clinical study reported a higher (statistically not significant) complete remission rate with IDR (75%) than DNR (59%) when both are used in combination chemotherapy in relapsed childhood ALL (Feig et al.. 1992 ). However, this study used increasing IDR doses to determine its MTD in combination chemotherapy, while the dose intensity of DNR was given below the MTD level. as shown by a significant higher toxicity in the group of children treated with IDR. Although our study suggests that the therapeutic index may not differ between IDR and DNR. we did not take into account other advantages of IDR compared with DNR, such as oral administration (Erttmann et al.. 1988; Pui et al.. 1988 ) and penetration of the cerebrospinal fluid (Reid et al.. 1990) . In contrast to childhood ALL. a large randomised study in adult acute myeloid leukaemia (AML) reported a superior response rate for IDR compared with DNR in remission induction chemotherapy (Berman et al.. 1991 
